Vertex Pharmaceutical’s New Hepatitis C Drug May Have Negative Effects
July 29, 2013
Vertex: FDA Puts Partial Hold on Study of Hepatitis C Drug
By Kristin Jones
Vertex Pharmaceuticals Inc. (VRTX) said the U.S. Food and Drug Administration has put a partial clinical hold on a mid-stage study of its experimental hepatitis C treatment VX-135 because of toxicity concerns.
Vertex shares fell 9.1% to $79.66 in after-hours trading.
The drug developer said the hold affects the 200-milligram dose of VX-135, a drug known as a nucleotide polymerase inhibitor, or “nuke,” which is designed to combat hepatitis C infection inside liver cells. Vertex joins Bristol-Myers Squibb Co. (BMY) and Idenix Pharmaceuticals Inc. (IDIX) in having to halt certain trials of nuke drugs because of toxicity concerns.
Continue reading this entire article:
Hepatitis C and Porphyria Cutanea Tarda
OraSure Technologies' OraQuick is the Only Federally Approved Rapid Hepatitis C Test